Eikon Therapeutics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Eikon Therapeutics presented Q3 2026 clinical progress: EIK1001 (TLR7/8 agonist) + pembrolizumab in NSCLC showed 63.1% ORR overall (55.6% non-squamous, 72.4% squamous) with 72-patient efficacy-evaluable population; EIK1003 (PARP1 inhibitor) monotherapy achieved 14.3% ORR in 49 evaluable patients, combination with paclitaxel 24.5% ORR in 53 evaluable patients; EIK1004 (CNS-penetrant PARP1), EIK1005 (WRN inhibitor), and EIK1006 (AR antagonist) advancing with 2026–2027 milestones including Phase 2/3 interim analyses, additional data readouts, and IND submission. No material financing, partnership, or ownership changes disclosed.
Why this rating
Early-stage clinical efficacy data support pipeline advancement; multiple Phase 2/3 trials ongoing. Relative to $850.8M asset base, results are encouraging but not yet transformational—no regulatory approvals, revenue-generating assets, or material partnership/financing announced. Ordinary clinical-stage progress.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.